Certain BCG-reactive responses are associated with bladder cancer prognosis

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Bacillus Calmette-Guérin (BCG) immunotherapy is standard for bladder cancer but patient response varies.
• The immune mechanisms underlying BCG treatment resistance are not fully understood.
• CD4+ T cells, with diverse cytokine profiles, play a crucial role in modulating immune responses.

Purpose of the Study:

• To investigate the CD4+ T-cell cytokine response in bladder cancer patients undergoing BCG treatment.
• To identify specific T-cell responses associated with treatment outcomes.
• To explore the role of macrophages and their polarization in influencing T-cell responses.

Main Methods:

• Analysis of CD4+ T-cell cytokine production (IFN-γ, IL-21, IL-4, IL-17, IL-10) in peripheral blood and tumor tissue after BCG stimulation.
• Assessment of macrophage surface marker expression (CD80, CD86, MHC II).
• Evaluation of macrophage-secreted cytokines (IL-12) and the impact of GM-CSF-mediated polarization on T-cell responses.

Main Results:

• Bladder cancer patients exhibit heterogeneous CD4+ T-cell responses to BCG.
• Higher expression of interferon-gamma (IFN-γ) and interleukin-21 (IL-21) by CD4+ T cells correlates with better patient prognosis.
• Tumor-infiltrating CD4+ T cells show distinct cytokine profiles compared to circulating T cells, with higher IL-10 and lower IFN-γ, IL-4, and IL-17.
• Macrophages from patients with high IFN-γ or IL-21 secretion produce more IL-12.
• Monocyte/macrophage polarization using GM-CSF enhances IFN-γ and IL-21 production by CD4+ T cells.

Conclusions:

• Specific CD4+ T-cell cytokine profiles are critical determinants of bladder cancer patient outcomes following BCG therapy.
• The tumor microenvironment influences CD4+ T-cell function.
• Monocyte/macrophage polarization represents a potential strategy to enhance anti-tumor immunity by modulating T-cell responses.